CytomX Therapeutics has revealed initial treatment using CX-2051, a selective EpCAM-targeted antibody-drug conjugate, in an early-stage trial involving individuals with progressive solid malignancies.
April 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Up to now, at the AACR meeting, updates on the clinical progress of several ADC drugs have been presented, involving targets such as HER2, BCMA, CD123, FRα, CCR7, Axl, etc.